Supplements · News, made simple
New FDA Warning for Popular GLP-1 Drugs
Learn about the new FDA warning regarding a rare eye condition linked to popular GLP-1 drugs like Ozempic and Wegovy.
HealthStylz Editors
· 2 min read
The short version
- FDA issues a new warning
- Rare eye condition noted
- Ask your doctor with questions
Based on reporting by Medical Xpress. We explain it in plain words; read the original for the full story.
Supplement Science
Supplement Evidence & Safety Profile
Comparing published human clinical trials with daily requirements and safe upper thresholds.
- Clinical Trial SupportHuman study evidence Well studied
- Daily Need vs Pill DoseNutritional balance Balanced
- Tolerable Upper Limit MarginSafety distance Safe margin
- Absorption with Whole FoodsBioavailability 88/100
Source: NIH Office of Dietary Supplements & U.S. Pharmacopeia.
Hello friends. Let us talk about a recent health update that might affect you or someone you love. Staying informed helps us take good care of our bodies every single day.
What's new
The Food and Drug Administration is asking makers of Ozempic, Wegovy and similar drugs to warn about a rare eye condition.
What it means for you
If you take these popular medications, you deserve to know all the latest facts. Always ask your doctor or pharmacist if you have any questions about your prescriptions.
One small thing to try
Take a few quiet minutes today to review your current medicines in a calm, well lit space so you feel prepared for your next chat with your care team.
Always review prescription warnings directly with your physician or pharmacist. If your care team includes nutrition goals alongside GLP-1 treatment, you can review the 0.8 to 1.6 g/kg protein reference ranges in our Protein Calculator and Calorie Deficit Planner.